Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Bristol-Myers Squibb Company (NYSE:BMY) had been left for dead on Wall Street, plagued by years of missed earnings and patent ...

Andrew Berndt will be representing the Sartell/St. Cloud Cathedral Nordic team at state after winning the section race. Several teammates also qualified.

Rep. Ro Khanna (D-Calif.) joins 'Squawk Box' to discuss President Trump's third week back in office, DOGE and Elon Musk's efforts to downsize the federal government, working across the aisle in the ...

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global pharmaceutical firm renowned for its innovative contributions to healthcare.

BOSTON, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.